Compare ACGL & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACGL | IQV |
|---|---|---|
| Founded | 2001 | 1982 |
| Country | Bermuda | United States |
| Employees | 8000 | 93000 |
| Industry | Property-Casualty Insurers | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 28.6B |
| IPO Year | N/A | 2013 |
| Metric | ACGL | IQV |
|---|---|---|
| Price | $89.62 | $183.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 16 |
| Target Price | $108.50 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | N/A | $6.77 |
| Revenue Next Year | $3.34 | $5.89 |
| P/E Ratio | ★ $8.45 | $112.06 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $82.45 | $151.58 |
| 52 Week High | $102.90 | $247.05 |
| Indicator | ACGL | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 31.51 | 62.40 |
| Support Level | $86.47 | $176.99 |
| Resistance Level | $94.33 | $191.78 |
| Average True Range (ATR) | 1.91 | 6.77 |
| MACD | -0.48 | 0.94 |
| Stochastic Oscillator | 1.90 | 91.37 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.